Authors: Chen Xi, Xie Zhenggao
DOI: 10.3760/cma.j.issn.2095-0160.2015.12.019
Published 2015-12-10
Cite as Chin J Exp Ophthalmol, 2015,33(12): 1144-1147.
Abstract [Download PDF] [Read Full Text]
As the newest anti-vascular endothelial grown factor (VEGF) drug, alfibercept binds to all forms of VEGF-A, VEGF-B, and PIGF.So far, intravitreal injection of alfibercept has already been used to treat certain opthalmological diseases, such as neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, central retinal vascular occlusion, diabetic macular edema, corneal neovascular, and retinopathy of prematurity.In this article, we contrasted alfibercept to the other anti-VEGF drugs, conducted a review of the recent research progress of alfibercept in opthalmological diseases and introduced the questions which still need to be solved and the probably research direction of alfibercept in the future.
Key words:
Alfibercept; Vascular endothelial growth factor; Intravitreal injection; Age-related macular degeneration
Contributor Information
Chen Xi
Department of Ophthalmology, Northern Jiangsu People’s Hospital, Department of Ophthalmology, Clinical Medical School of Yangzhou University, Yangzhou 225001, China
Xie Zhenggao
(Read 21 times, 1 visits today)